1887

1 : Hepatitis C Virus and Chronic Liver Disease

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Ebook: Choose a downloadable PDF or ePub file. Chapter is a downloadable PDF file. File must be downloaded within 48 hours of purchase

Buy this Chapter
Digital (?) $15.00

Preview this chapter:
Zoom in
Zoomout

Hepatitis C Virus and Chronic Liver Disease, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555816995/9781555812423_Chap01-1.gif /docserver/preview/fulltext/10.1128/9781555816995/9781555812423_Chap01-2.gif

Abstract:

This chapter focuses on disease burden and the natural history of chronic liver disease due to hepatitis C virus (HCV) infection and highlights recent advances in therapy. Hepatitis C is the indication for an increasing proportion of liver transplants in the United States, accounting for 36% of all transplants in 1999. A study of anti-HCV-positive adolescents and young adults (mean age of 19.8 years) who had received blood transfusions as infants or young children showed that less than 60% had persistent infection. Of 17 patients who underwent liver biopsies, only two had portal fibrosis; both patients also had congestive heart failure. One recent review of published studies that evaluated progression to cirrhosis in cohorts of hepatitis C patients defined four categories based on how patients were recruited: cross-sectional studies of patients seen in referral practices; longitudinal studies of patients with posttransfusion hepatitis; case series of blood donors found at the time of screening to be anti-HCV positive; and community-based cohorts. Considerable advances in the treatment of hepatitis C have been made over the past several years. At the time of 1997 National Institutes of Health Consensus Development Conference, the recommended therapy of a 48-week course of interferon alpha three times a week resulted in a sustained virological response (SVR) of 12 to 16%. With optimal therapy of pegylated interferon and ribavirin, patients infected with genotype 1 have lower response rates (40 to 45%) than patients infected with genotype 2 or 3 (approximately 80%).

Citation: Bell B. 2004. Hepatitis C Virus and Chronic Liver Disease, p 1-11. In Scheld W, Murray B, Hughes J (ed), Emerging Infections 6. ASM Press, Washington, DC. doi: 10.1128/9781555816995.ch1
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

Figures

Image of Figure 1
Figure 1

Primary etiology of patients newly diagnosed with chronic liver disease: New Haven, Conn., and Kaiser, Alameda, Calif., 1999 ( = 342). HBV, hepatitis B virus; NAFLD, nonalcoholic fatty liver disease; alcohol, excessive alcohol intake. Other etiologies include primary biliary cirrhosis, primary sclerosing cholangitis, autoimmune hepatitis, granulomatous hepatitis, hemochromatosis, sarcoidosis, drug-induced hepatitis, cryptogenic, alpha-1-antitrypsin deficiency, and hepatocellular carcinoma. Findings are preliminary.

Citation: Bell B. 2004. Hepatitis C Virus and Chronic Liver Disease, p 1-11. In Scheld W, Murray B, Hughes J (ed), Emerging Infections 6. ASM Press, Washington, DC. doi: 10.1128/9781555816995.ch1
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 2
Figure 2

Effect of HCV infection incidence on future prevalence of infection. Reprinted in part from reference 3, with permission from Elsevier.

Citation: Bell B. 2004. Hepatitis C Virus and Chronic Liver Disease, p 1-11. In Scheld W, Murray B, Hughes J (ed), Emerging Infections 6. ASM Press, Washington, DC. doi: 10.1128/9781555816995.ch1
Permissions and Reprints Request Permissions
Download as Powerpoint
Image of Figure 3
Figure 3

Natural history of HCV infection related to age at infection from cohort studies ( ).

Citation: Bell B. 2004. Hepatitis C Virus and Chronic Liver Disease, p 1-11. In Scheld W, Murray B, Hughes J (ed), Emerging Infections 6. ASM Press, Washington, DC. doi: 10.1128/9781555816995.ch1
Permissions and Reprints Request Permissions
Download as Powerpoint

References

/content/book/10.1128/9781555816995.chap01
1. Alter, H. J.,, and L. B. Seeff. 2000. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin. Liver Dis. 20:1735.
2. Alter, M. J.,, D. Kruszon-Moran,, O. V. Nainan,, G. M. McQuillan,, F. Gao,, L. A. Moyer,, R. A. Kaslow,, and H. S. Margolis. 1999. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med. 341:556562.
3. Armstrong, G. L.,, M. J. Alter,, G. M. McQuillan,, and H. S. Margolis. 2000. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 31:777782.
4. Bellentani, S.,, G. Pozzato,, G. Saccoccio,, M. Crovatto,, L. S. Croce,, L. Mazzoran,, F. Masutti,, G. Cristianini,, and C. Tiribelli. 1999. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Gut 44:874880.
5. Benhamou, Y.,, M. Bochet,, V. Di Martino,, F. Charlotte,, F. Azria,, A. Coutellier,, M. Vidaud,, F. Bricaire,, P. Opolon,, C. Katlama, and T. Poynard for the MULTIVIRC Group. 1999. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology 30:10541058.
6. Bica, I.,, B. McGovern,, R. Dhar,, D. Stone,, K. McGowan,, R. Scheib,, and D. R. Snydman. 2001. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin. Infect. Dis. 32:492497.
7. Bissell, D. M. 1999. Sex and hepatic fibrosis. Hepatology 29:988989.
8. Centers for Disease Control and Prevention. 1998. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Morb. Mortal. Wkly. Rep. 47(RR-19):139.
9. Centers for Disease Control and Prevention. 1999. Births and deaths: preliminary data for 1998. Nat. Vital Stat. Rep. 47:148.
10. Corrao, G.,, and S. Arico. 1998. Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology 27:914919.
11. Darby, S. C.,, D. W. Ewart,, P. L. Giangrande,, R. J. Spooner,, C. R. Rizza,, G. M. Dusheiko,, C. A. Lee,, C. A. Ludlam,, and F. E. Preston. 1997. Mortality from liver cancer and liver disease in haemophilic men and boys in the UK given blood products contaminated with hepatitis C. Lancet 350:14251431.
12. Di Bisceglie, A. M.,, Z. D. Goodman,, K. G. Ishak,, J. H. Hoofnagle,, J. J. Melpolder,, and H. J. Alter. 1991. Long-term clinical and histopathological follow-up of chronic posttransfusion hepatitis. Hepatology 14:969974.
13. Di Bisceglie, A. M.,, and J. H. Hoofnagle. 2002. Optimal therapy of hepatitis C. Hepatology 36:S121S127.
14. Freeman, A. J.,, G. J. Dore,, M. G. Law,, M. Thorpe,, J. Von Overbeck,, A. R. Lloyd,, G. Marinos,, and J. M. Kaldor. 2001. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 34:809816.
15. Frieden, T. R.,, L. Ozick,, C. McCord,, O. V. Nainan,, S. Workman,, G. Comer,, T. P. Lee,, K.-S. Byun,, D. Patel,, and K. J. Henning. 1999. Chronic liver disease in central Harlem: the role of alcohol and viral hepatitis. Hepatology 29:883888.
16. Graham, C. S.,, L. R. Baden,, E. Yu,, J. M. Mrus,, J. Carnie,, T. Heeren,, and M. J. Koziel. 2001. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin. Infect. Dis. 33:562569.
17. Harris, D. R.,, R. Gonin,, H. J. Alter,, E. C. Wright,, Z. J. Buskell,, F. B. Hollinger,, and L. B. Seeff. 2001. The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. Ann. Intern. Med. 134:120124.
18. Heathcote, E. J.,, M. L. Shiffman,, W. G. E. Cooksley,, G. M. Dusheiko,, S. S. Lee,, L. Balart,, R. Reindollar,, R. K. Reddy,, T. L. Wright,, A. Lin,, J. Hoffman,, and J. De Pamphilis. 2000. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N. Engl. J. Med. 343:16731680.
19. Hopf, U.,, B. Moller,, D. Kuther,, R. Stemerowicz,, H. Lobeck,, A. Ludtke-Handjery,, E. Walter,, H. E. Blum,, M. Roggendorf,, and F. Deinhardt. 1990. Long-term follow-up of posttransfusion and sporadic chronic hepatitis non-A, non-B and frequency of circulating antibodies to hepatitis C virus. J. Hepatol. 10:6976.
20. Kenny-Walsh, E., and the Irish Hepatology Research Group. 1999. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N. Engl. J. Med. 340:12281233.
21. Kim, W. R.,, R. S. Brown,, N. A. Terrault,, and H. El-Serag. 2002. Burden of liver disease in the United States: summary of a workshop. Hepatology 36:227242.
22. Kim, W. R. 2002. The burden of hepatitis C in the United States. Hepatology 36:S30S34.
23. Koretz, R. L.,, H. Abbey,, E. Coleman,, and G. Gitnick. 1993. Non-A, non-B post-transfusion hepatitis. Looking back on the second decade. Ann. Intern. Med. 119:110115.
24. Lesens, O.,, M. Deschenes,, M. Steben,, G. Belanger,, and C. M. Tsoukas. 1999. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J. Infect. Dis. 179:12541258.
25. Lindsay, K. L.,, C. Trepo,, T. Heintges,, M. L. Shiffman,, S. C. Gordon,, J. C. Hoefs,, E. R. Schiff,, Z. D. Goodman,, M. Laughlin,, R. Yao,, J. K. Albrecht, and The Hepatitis Interventional Therapy Group. 2001. A randomized, double blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 34:395403.
26. Makris, M.,, F. E. Preston,, F. R. Rosendaal,, J. C. Underwood,, K. M. Rice,, and D. R. Triger. 1996. The natural history of chronic hepatitis C in haemophiliacs. Br. J. Haematol. 94:746752.
27. Manns, M. P.,, J. G. McHutchison,, S. C. Gordon,, V. K. Rustgi,, M. Shiffman,, R. Reindollar,, Z. D. Goodman,, K. Koury,, M. Ling,, and J. K. Albrecht. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 358:958965.
28. Monga, H. K.,, M. C. Rodriguez-Barradas,, K. Breaux,, K. Khattack,, C. L. Troisi,, M. Velez,, and B. Yoffe. 2001. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin. Infect. Dis. 33:240247.
29. National Institutes of Health. 1997. National Institutes of Health Consensus Development Conference Panel Statement: Management of Hepatitis C. Hepatology 26(Suppl. 1):2S10S.
30. Pol, S.,, B. Lamorthe,, N. T. Thi,, V. Thiers,, F. Carnot,, H. Zylberberg,, P. Berthelot,, C. Brechot,, and B. Nalpas. 1998. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users. J. Hepatol. 28:945950.
31. Poynard, T.,, P. Bedossa, and P. Opolon for the OBSVIRC, METAVIR, CLINIVIR and DOSVIRC Groups. 1997. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 349:825832.
32. Poynard, T.,, V. Ratziu,, F. Charlotte,, Z. Goodman,, J. McHutchison,, and J. Albrecht. 2001. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J. Hepatol. 34:730739.
33. Seeff, L. B.,, R. N. Miller,, C. S. Rabkin,, Z. Buskell-Bales,, K. D. Straley-Eason,, B. L. Smoak,, L. D. Johnson,, S. R. Lee,, and E. L. Kaplan. 2000. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann. Intern. Med. 132:105111.
34. Seeff, L. B.,, F. B. Hollinger,, H. J. Alter,, E. C. Wright,, C. M. B. Cain,, Z. J. Buskell,, K. G. Ishak,, F. L. Iber,, D. Toro,, A. Samanta,, R. L. Koretz,, R. P. Perillo,, Z. D. Goodman,, R. G. Knodell,, G. Gitnick,, T. R. Morgan,, E. R. Schiff,, S. Lasky,, C. Stevens,, R. Z. Vlahcevic,, E. Weinshel,, T. Tanwandee,, H. J. Lin,, and L. Barbosa. 2001. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a National Heart, Lung, and Blood Institute collaborative study. Hepatology 33:455463.
35. Sherman, K. E.,, S. D. Rouster,, R. T. Chung,, and N. Rajicic. 2002. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the U.S. adult AIDS Clinical Trials Group. Clin. Infect. Dis. 34:831837.
36. Soriano, V.,, J. García-Samaniego,, E. Valencia,, R. Rodríguez-Rosado,, F. Muñoz,, and J. González-Lahoz. 1999. Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur. J. Epidemiol. 15:14.
37. Soto, B.,, A. Sánchez-Quijano,, L. Rodrigo,, J. A. Del Olmo,, M. García-Bengoechea,, J. Hernández-Quero,, C. Rey,, M. A. Abad,, M. Rodriguez,, M. Sales Gilabert,, F. González,, P. Mirón,, A. Caruz,, F. Relimpio,, R. Torronteras,, M. Leal,, and E. Lissen. 1997. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J. Hepatol. 26:15.
38. Thomas, D. L.,, J. Astemborski,, R. M. Rai,, F. A. Anania,, M. Schaeffer,, N. Galai,, K. Nolt,, K. E. Nelson,, S. A. Strathdee,, L. Johnson,, O. Laeyendecker,, J. Boitnott,, L. E. Wilson,, and D. Vlahov. 2000. The natural history of hepatitis C virus infection: host, viral and environmental factors. JAMA 284:450456.
39. Tong, M. J.,, N. S. El-Farra,, A. R. Reikes,, and R. L. Co. 1995. Clinical outcomes after transfusion-associated hepatitis C. N. Engl. J. Med. 332:14631466.
40. Tremolada, F.,, C. Casarin,, A. Alberti,, C. Drago,, A. Tagger,, M. L. Ribero,, and G. Realdi. 1992. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J. Hepatol. 16:273281.
41. Vogt, M.,, T. Lang,, G. Frosner,, C. Klingler,, A. F. Sendl,, A. Zeller,, B. Wiebecke,, B. Langer,, H. Meisner,, and J. Hess. 1999. Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening. N. Engl. J. Med. 341:866870.
42. Wiese, M.,, F. Berr,, M. Lafrenz,, H. Porst,, and U. Oesen. 2000. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. Hepatology 32:9196.
43. Wiley, T. E.,, M. McCarthy,, L. Breidi,, and T. J. Layden. 1998. Impact of alcohol on the histological and clinical progression of hepatitis C infection. Hepatology 28:805809.
44. Zeuzem, S.,, S. V. Feinman,, J. Rasenack,, E. J. Heathcote,, M.-Y. Lai,, E. Gane,, J. O'Grady,, J. Reichen,, M. Diago,, A. Lin,, J. Hoffman,, and M. J. Brunda. 2000. Peginterferon alfa-2a in patients with chronic hepatitis C. N. Engl. J. Med. 343:16661672.

Tables

Generic image for table
Table 1

Chronic liver disease and cirrhosis mortality, United States, 1998

Citation: Bell B. 2004. Hepatitis C Virus and Chronic Liver Disease, p 1-11. In Scheld W, Murray B, Hughes J (ed), Emerging Infections 6. ASM Press, Washington, DC. doi: 10.1128/9781555816995.ch1
Generic image for table
Table 2

Burden associated with HCV infection, United States

Citation: Bell B. 2004. Hepatitis C Virus and Chronic Liver Disease, p 1-11. In Scheld W, Murray B, Hughes J (ed), Emerging Infections 6. ASM Press, Washington, DC. doi: 10.1128/9781555816995.ch1

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error